| P50 | author | Takayuki Yoshimoto | Q55477598 |
| | Yukino Chiba | Q62754098 |
| P2093 | author name string | Izuru Mizoguchi | |
| | Junichiro Mizuguchi | |
| | Noriko Morishima | |
| | Mingli Xu | |
| P2860 | cites work | Monoclonal Anti–Interleukin 23 Reverses Active Colitis in a T Cell–Mediated Model in Mice | Q22250938 |
| | Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 | Q24290619 |
| | Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells | Q24295111 |
| | Cutting edge: A transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway | Q24300905 |
| | A pivotal role for interleukin-27 in CD8+ T cell functions and generation of cytotoxic T lymphocytes | Q37747078 |
| | IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities | Q39785695 |
| | Antiproliferative activity of IL-27 on melanoma | Q39985822 |
| | Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. | Q40124037 |
| | Antiangiogenic and antitumor activities of IL-27. | Q40271796 |
| | Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. | Q40315635 |
| | A role for IL-27 in early regulation of Th1 differentiation | Q40388468 |
| | Augmentation of effector CD8+ T cell generation with enhanced granzyme B expression by IL-27. | Q40395233 |
| | Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cytokine genes in murine colon carcinoma cells. | Q40453129 |
| | Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. | Q40462490 |
| | IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells | Q40483240 |
| | An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells | Q40517735 |
| | Antitumor and antimetastatic activity of interleukin 12 against murine tumors | Q41906195 |
| | Role of interferon-gamma in interleukin 12-induced pathology in mice. | Q42789370 |
| | Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma | Q43870189 |
| | WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production | Q44721986 |
| | Swords into plowshares: IL-23 repurposes tumor immune surveillance | Q46951146 |
| | Potent antitumor activity of interleukin-27. | Q47210067 |
| | The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection | Q47388000 |
| | Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells | Q47887109 |
| | Cutting Edge: Role of IL-27/WSX-1 Signaling for Induction of T-Bet Through Activation of STAT1 During Initial Th1 Commitment | Q24301442 |
| | Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells | Q24338229 |
| | Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells | Q27860460 |
| | Inflammation and cancer: back to Virchow? | Q28036756 |
| | Antitumor and antimetastatic activity of IL-23 | Q28185593 |
| | Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 | Q28213628 |
| | IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells | Q28214882 |
| | Transforming growth factor-beta induces development of the T(H)17 lineage | Q28237370 |
| | IL-23 promotes tumour incidence and growth | Q28239522 |
| | The inhibitory cytokine IL-35 contributes to regulatory T-cell function | Q28258462 |
| | Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain | Q29614225 |
| | The STATs of cancer--new molecular targets come of age | Q29614601 |
| | Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity | Q29619700 |
| | Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis | Q29620506 |
| | Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. | Q33185772 |
| | The toxicology of interleukin-12: a review | Q33657643 |
| | Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity | Q34334817 |
| | The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses | Q34468846 |
| | Regulatory T cells in cancer | Q34550248 |
| | Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells | Q34556912 |
| | Interleukin-12 in anti-tumor immunity and immunotherapy. | Q34568708 |
| | Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy | Q34723863 |
| | The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses | Q35582560 |
| | GM-CSF gene-transduced tumor vaccines | Q36166960 |
| | IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy | Q36167306 |
| | Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes | Q36356764 |
| | Regulatory T cells, tumour immunity and immunotherapy | Q36430144 |
| | Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. | Q36691086 |
| | Interleukin-35: odd one out or part of the family? | Q37073886 |
| | New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation | Q37133882 |
| | Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment | Q37169987 |
| | Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow | Q37315226 |
| | Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice. | Q37349027 |
| | Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity | Q51798657 |
| | Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity | Q54502471 |
| | A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. | Q55045567 |
| | Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10 | Q56930023 |
| | Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients | Q56966393 |
| | Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial | Q68091629 |
| | A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone | Q68815180 |
| | Interleukin-12: role of interferon-gamma in IL-12 adverse effects | Q73162615 |
| | Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system | Q80102518 |
| | Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells | Q80752252 |
| | The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity | Q80884527 |
| | Sciencescope | Q80947816 |
| | IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells | Q81283203 |
| | IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation | Q81317209 |
| | Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells | Q81578755 |
| | Reinforcing suppression using regulators: a new link between STAT3, IL-23, and Tregs in tumor immunosuppression | Q83278302 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | interleukin 12 | Q2409681 |
| | antigen-presenting cell | Q1047791 |
| | neoplasm | Q1216998 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 4779-4788 | |
| P577 | publication date | 2010-09-14 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Clinical and Developmental Immunology | Q15754140 |
| P1476 | title | Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27 | |
| P478 | volume | 2010 | |